From sea to seed: A comparability study of animal-derived squalene with PhytoSquene ® plant-based squalene in adjuvant formulations

Overview

PhytoSquene^® is a plant-based squalene developed by Evonik for use in pharmaceutical applications such as vaccine adjuvants. As the world’s first plant-based squalene available in GMP quality, PhytoSquene^® offers pharmaceutical companies the opportunity to improve the safety and sustainability of their products.

In this webinar, our experts present data from a study that compares the physical chemical attributes and in vitro toxicity effects of GMP-grade PhytoSquene^® with animal-derived squalene.

In this webinar you will learn about:

Squalene and its applications in vaccine adjuvants
The challenges with using shark-derived squalene
Comparability studies showing that PhytoSquene^® matches the performance of animal-derived squalene

Experts featuring this session

Dr. Rima Jaber
Global Product Manager Lipids
Evonik Health Care
Vita

Rima joined Evonik in 2009 and has held multiple R&D roles in Germany and abroad. She has over 10 years’ experience in parenteral and complex oral formulations and the handling of highly potent active pharmaceutical ingredients.

In her previous positions, she also gained experience in managing the development of new biomaterials for medical device applications, managing publicly funded projects such as BMBF, EU and Australian linkage grants, and new manufacturing methods, biotransformation and plant cell fermentation.

Since 2022, Rima has been responsible for the global product management of lipids at Evonik’s Health Care business line.

Rima’s academic background is in pharmaceutical chemical engineering. She obtained her Ph.D. from the university of Jena in Germany, where she specialized in optimizing processes for biodegradable polymers including for manufacturing and formulation. Rima is the author of several research papers and patent applications.

Dr. Nooshin Ghodsian
Scientist
Evonik Health Care
Vita

Nooshin Ghodsian joined Evonik in 2022 and works as a pharmaceutical scientist for the Health Care business. She has significant expertise in the field of human genetics, with a focus on the pathobiological processes of cardiometabolic diseases.

Her career began with a BSc in cellular and molecular biology from her home country, Iran, followed by a Master of Science in human genetics from University Putra Malaysia, where she identified genetic variations associated with hypertension and diabetes.

Nooshin then pursued a Ph.D. in Biochemistry at the University of Canterbury, New Zealand, where she studied the cellular and molecular mechanisms of scavenger receptors related to atherosclerosis.

Following her doctoral studies, she transitioned to Laval University in Quebec, Canada, to carry out analytical and epidemiological research. During her postdoctoral fellowship, she led a large genetic association study that uncovered new genetic loci linked to non-alcoholic fatty liver disease (NAFLD) employing cutting-edge methodologies like genome-wide and transcriptome-wide association studies.